Excessive mucus production is a shared and dangerous feature of asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and acute respiratory infections, linked to worse lung function and higher mortality. A new review published in Pediatric Discovery highlights the epidermal growth factor receptor (EGFR) signaling pathway as a central control point for airway mucus hypersecretion and assesses drugs designed to block it. The review, from researchers at Children's Hospital of Chongqing Medical University and affiliated laboratories in Chongqing, China, was accepted on 10 May 2025 and published (DOI: 10.1002/pdi3.70007) in the journal's 2026 issue.
About half of people with COPD show mucus hypersecretion, and affected patients face a mortality risk about 3.5 times higher than those without it. In asthma, mucus plugs can contribute to fatal airway obstruction. Current options—bronchodilators, hypertonic saline, and mucolytics—mainly relieve symptoms and can cause cardiac, visual, urinary, and metabolic adverse effects. No specific therapy reliably controls mucus overproduction. The review therefore examines whether blocking a convergent inflammatory pathway can reduce mucus without merely treating cough and sputum.
The authors detail how EGFR activation drives goblet cell hyperplasia (GCH) and mucin gene expression through Ras/Raf/MAPK/ERK signaling and the transcription factor Sp1, promoting MUC5AC and MUC2 transcription, while also suppressing FOXA2. In preclinical models, an anti-EGFR single-chain antibody fragment displayed on ferritin nanoparticles eased asthma features and reduced GCH and mucus. Tyrosine kinase inhibitors (TKIs) including gefitinib, erlotinib, and afatinib reduced MUC5AC and mucus in asthma, COPD, acrolein, and viral-infection models; erlotinib restored claudin 1, a barrier protein whose loss accompanies GCH. Monoclonal antibodies block the extracellular domain, whereas TKIs compete with ATP at the receptor's tyrosine kinase site. A retrospective lung-cancer study suggested gefitinib and afatinib can inhibit mucus hypersecretion before tumor shrinkage.
Human evidence remains limited: inhaled BIBW 2948 was poorly tolerated in COPD, while the downstream inhibitor Bio11006 reached phase IIb. The authors emphasize that efficacy must be balanced against skin, gastrointestinal, hepatic, and pulmonary toxicity. They said the central opportunity is to turn a shared inflammatory convergence point into a selective airway therapy, but cautioned that existing TKIs carry off-target effects and that no successful EGFR-TKI trial has yet been reported in human asthma or COPD. Future work should prioritize low off-target molecules, optimized delivery devices, and clinical trials that measure both mucus outcomes and systemic safety.
Clinically, EGFR-targeted drugs could complement bronchodilators and mucolytics by reducing the source of excess mucus rather than only clearing it. The most plausible near-term path is inhaled or airway-selective delivery, which may limit toxicity associated with systemic TKIs. Patients with severe asthma, COPD with mucus plugs, CF, or virus-driven exacerbations might benefit most, but trials will need to measure mucin burden, lung function, exacerbations, and adverse events. Nanoparticle and antibody-fragment platforms could improve targeting, yet regulators and clinicians will need robust evidence that mucus reduction translates into fewer exacerbations and better survival. The review's implication is clear: EGFR is a promising target, not yet a proven routine treatment. The research was supported by the Natural Science Foundation of Chongqing, the Scientific and Technological Research Program of Chongqing Municipal Education Commission, the Chongqing Science and Health Joint Medical Research Project, and the National Key Research and Development Program of China. For more information on innovation facilitation, see http://chuanlink-innovations.com.
